



Nasal NARCAN Spray Distribution on the BP: *Why and How*

Dartmouth Hitchcock Medical Center

Birthing Pavilion

In Partnership with NH DHHS, Doorway NH and HRSA


Kate Olivia Stokes, RN, BSN, MPH



[Drug Overdose Deaths in the U.S. Up 30% in 2020 \(cdc.gov\)](https://www.cdc.gov/drugoverdose/deaths)

- **93,331 drug overdose deaths in the United States during 2020**
- **29.4% increase from the 72,151 deaths predicted in 2019**

Number and age-adjusted rates of drug overdose deaths by state, US 2019



Range Category

6.9 to 11.0

13.6 to 16.0

18.6 to 21.0

11.1 to 13.5

16.1 to 18.5

21.1 to 57.0

Maternal Mortality

- US has the highest rate of maternal death of any industrialized country
- New Hampshire ranks 19th in the in U.S. for maternal mortality

Sources:

- 1) The World Bank. Maternal Mortality Ratio, Modeled estimate per 100,000 live births, 2017. <https://data.worldbank.org>
- 2) State Summaries New Hampshire 2018 Health of Women and Children Report. <https://www.americashealthrankings.org>

Why Nasal NARCAN?



HARM REDUCTION

- Most maternal deaths in NH occur
 - Postpartum
 - Due to Overdose
 - Due to Suicide

Alliance for Innovation on Maternal Health (AIM)

- National data-driven maternal safety and quality improvement initiative
- Works to reduce preventable maternal mortality and severe morbidity
- AIM works to promote respectful care for all birthing persons, and eliminate disparities in perinatal outcomes

Source: NH Maternal Mortality Review Committee (CDC-funded)

AGONISTS.....ANTAGONISTS

Full Agonist

Codeine
Fentanyl
Heroin
Hydrocodone
Hydromorphone
Levorphanol
Meperidine
Methadone
Morphine
Oxycodone
Oxymorphone

Partial Agonist

Buprenorphine
Butorphanol
Pentazocine
Tramadol

Mixed Agonist

Buprenorphine
Butorphanol
Nalbuphine
Pentazocine


Antagonist

Naloxone
Naltrexone

****Do NOT use Nubain for people on MAT (Subutex, Suboxone, or Methadone).
It causes rapid withdrawal!**


Narcan reversing an overdose

Narcan has a stronger affinity to the opioid receptors than opioids like heroin or Percocet, so it knocks the opioids off the receptors for a short time. This allows the person to breathe again and reverses the overdose.



Source: [Understanding Naloxone - National Harm Reduction Coalition](#)

What are you asking me to do?



Ask patients with
SUD hx if they want
to talk with someone
about taking home
nasal NARCAN

Educate about
NARCAN storage
and administration

Document
that you
provided the
education or
that the
patient
declined the
NARCAN

Give NARCAN
to *provider*

How NARCAN Spray is Distributed on the BP

- We have a ***Standing Order*** for NARCAN Nasal Spray from the State of NH
- DHMC **Policy #22887/Procedure #23372** for NARCAN Nasal Spray Distribution

Who gets NARCAN?

- Screen all patients who come to the inpatient obstetrics unit
- **Script** to use with patients:
 - “Opioid overdose is a serious problem in our communities. Naloxone can reverse an overdose. Would you like to talk to someone about having Naloxone? It can be for friends, family members, yourself or other people in the community.”
- Screen all patients through eDH:
 - ‘Are you or is someone you know at risk of witnessing or experiencing an overdose?’

Who does what?

- 1) **Nurse or Provider** *educates* patients and families and documents in eDH progress note using .NARCANED smart phrase
- 2) ****Only Providers give the NARCAN to the patient or family member****
 - Nurses can administer, but cannot dispense medications

Patient Education

- Effects of opioids
- Mitigation strategies to reduce the risk of opioid overdose
- Recognizing signs and symptoms of opioid overdose
- Overdose response steps
- Use of naloxone HCL
- Mechanism of action
- When to administer
- How to administer
- Possible side effects
- Proper storage, handling, and disposal
- When and how to get a prescription refill

2 Doses of NARCAN per Box



[Narcan in Communities - Fix for Addiction](#) Photo by Emily Rowan

NARCAN[®] (naloxone HCl) **NASAL SPRAY**

QUICK START GUIDE Opioid Overdose Response Instructions

Use NARCAN[®] (naloxone hydrochloride) Nasal Spray for known or suspected opioid overdose in adults and children.

Important: For use in the nose only.

Do not remove or test the NARCAN Nasal Spray until ready to use.

1 Identify Opioid Overdose and Check for Response

Ask person if he or she is okay and shout name.

Shake shoulders and firmly rub the middle of their chest.

Check for signs of an opioid overdose:

- Will not wake up or respond to your voice or touch
- Breathing is very slow, irregular, or has stopped
- Center part of their eye is very small, sometimes called "pinpoint pupils"

Lay the person on their back to receive a dose of NARCAN Nasal Spray.



2 Give NARCAN Nasal Spray

REMOVE NARCAN Nasal Spray from the box.

Peel back the tab with the circle to open the NARCAN Nasal Spray.

Hold the NARCAN Nasal Spray with your thumb on the bottom of the red plunger and your first and middle fingers on either side of the nozzle.

Gently insert the tip of the nozzle into either nostril.

- Tilt the person's head back and provide support under the neck with your hand. Gently insert the tip of the nozzle into **one nostril**, until your fingers on either side of the nozzle are against the bottom of the person's nose.

Press the red plunger firmly to give the dose of NARCAN Nasal Spray.

- Remove the NARCAN Nasal Spray from the nostril after giving the dose.



3 Call for emergency medical help, Evaluate, and Support

Get emergency medical help right away.

Move the person on their side (recovery position) after giving NARCAN Nasal Spray.

Watch the person closely.

If the person does not respond by waking up, to voice or touch, or breathing normally another dose may be given. NARCAN Nasal Spray may be dosed every 2 to 3 minutes, if available.

Repeat Step 2 using a new NARCAN Nasal Spray to give another dose in the other nostril. If additional NARCAN Nasal Sprays are available, repeat step 2 every 2 to 3 minutes until the person responds or emergency medical help is received.



ADAPT
PHARMA

For more information about NARCAN Nasal Spray, go to www.narcan.com, or call 1-844-4NARCAN (1-844-462-7226). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

©2015 ADAPT Pharma, Inc. NARCAN[®] and Adapt Pharma are registered trademarks of Adapt Pharma Operations Limited. A1115



In binder!

Patient Education Talking Points

- Effects of opioids (fentanyl, heroin, oxycodone, etc)
 - Slowed breathing, drowsiness
- Mitigation strategies to reduce the risk of opioid overdose
 - Don't use alone. Start with a small amount and go slow.
- Recognizing signs and symptoms of opioid overdose
 - Will not wake up or respond to voice or touch.
 - Breathing is very slow, irregular or has stopped.
 - Pupils of eyes are very small, like "pin-points".
- Overdose response steps
 - Ask the person if they are okay and shout their name.
 - Shake them and firmly rub their chest to see if they respond.
- Use of naloxone HCL
 - **If they do not respond, give NARCAN. It is safe even if you do not know what medication they took.** It could save their life.
 - **It is safe for pregnant people to get NARCAN.**
- Mechanism of action
 - NARCAN knocks the opioids off the opioid receptors to reverse the overdose.
- When to administer
 - Immediately after confirming that they are not responding and may have overdosed.
- How to administer
 - See NARCAN medication insert (*on reverse side of this page*).
 - **Repeat dose every 2-3 minutes until they respond.**
- Possible side effects
 - Rapid withdrawal including nausea, vomiting, pain, confusion
- Proper storage, handling, and disposal
 - **Do NOT store in the car.** Do NOT freeze or keep in a place with temperature over 80.
 - Store in a cool place away from bright light.
- When and how to get a prescription refill
 - Doorway NH provides NARCAN
 - Many pharmacies provide it without a prescription or Call 211

OPIOID OVERDOSE + PREGNANCY



When overdoses happen, giving naloxone (Narcan®) saves lives
- including the lives of pregnant people and their babies


Place the person in the recovery position on their left side to improve blood flow to the placenta.



If you think they have injured their back or neck don't move them.

Call **911**

Tell the dispatcher that you are with a pregnant person who is not breathing and you need paramedics.



You do not need to tell them that this may be a drug poisoning or overdose. If you do they may send police officers.

Stay with the person or find someone who can until paramedics arrive.



Tell the responders that the person takes opioids and may have taken too much and overdosed.



Respond to overdose in a pregnant person exactly the same as you would for anyone else.



Academy of Perinatal
Harm Reduction

www.harmreduction.org
www.perinatalharmreduction.org

**NATIONAL
HARM REDUCTION
COALITION**

Documentation in eDH

eDH Progress Note

Smart Phrase **.NARCANED**

Patient @name@
@mrn@

@name@ requested information about naloxone HCL (Narcan) nasal spray today.
Patient {WAS/WAS NOT:2100118327} accompanied in the office by her {companion:315061}.
Education was provided regarding all of the following:

- Effects of opioids
- Mitigation strategies to reduce the risk of opioid overdose
- Recognizing signs and symptoms of opioid overdose
- Overdose response steps
- Use of naloxone HCL
- Mechanism of action
- When to administer
- How to administer
- Possible side effects
- Proper storage, handling, and disposal
- When and how to get a prescription refill

Teaching methods used to provide education included explanation, demonstration, and handouts.

Patient {WAS/WAS NOT:2100118327} able to explain the indication for, and proper use of, naloxone nasal spray.

Patient {MICU_DID_DID NOT:26015} accept Narcan kit.

Patient {WAS/WAS NOT:2100118327} able to return demonstrate proper administration technique of naloxone HCL nasal spray with

Patient {WAS/WAS NOT:2100118327} provided two (2) 4-mg doses of naloxone HCL nasal spray.
Lot number: *** Expiration date: ***

@name@ knows how to contact OB/GYN Nurse Triage should she have further questions or concerns.

@MES@



Date _____	
# of Kits Received _____	
Who is the Kit for?	
Circle all that apply.	Self; Friend, Family Member, Other
If the kit is for yourself what is the Month and Year of Your Birth? Example "05/1990"	DOB:
What is your gender? Circle one:	Male, Female, Transgender, Other, Refused to Answer.
If the kit(s) is for you, do you have insurance?	Yes, No, Not Sure
If yes to above, what type of insurance do you have?	Medicaid, Private Insurance, Other
If you have insurance who is your insurance provider?	Write in the name of your insurance provider:
How many times have you overdosed?	Write in the number:
Number of times Narcan/Naloxone has been administered to you to reverse an overdose,?	Write in the number:
What was the primary reason you started using Opioids?	Circle the best explanation or write in your own explanation. Coping with mental health problems Depression & grief Easier to evade detection than marijuana Given by partner Life struggles Pain management following injury or surgery Experimented in School/College or Other setting Taking any pills she/he could find Unavailable Other
Where did you first get opioids?	Circle the best explanation or write in your own explanation. Partner Ex-partner Friend(s) Own Prescription Someone Else's Prescription Unavailable Other

NH DHHS Data Collection Form

NARCAN NASAL SPRAY
CHECK LIST

- ☐ Remove kit. Update inventory sheet with lot number and expiration date.
- ☐ Meet with patient. RN or Provider provides education.
- ☐ Provider dispenses Narcan kit.
- ☐ Complete Data Collection Form with patient (for the State of NH).
- ☐ Document in EMR, using smartphrase .NARCANED.
- ☐ Place Data Collection Form in the Narcan Distribution folder.

(Don't worry, there's a reminder check-list in the front of the 'Narcan Distribution' binder.)

***Give one
to every
patient
who goes
home with
narcotics!***



Safe. Convenient. Effective.

Deterra[®] is the solution

Closing the loop on the pharmaceutical lifecycle



Vetted, Endorsed, and Recommended

- The manufacturers of Deterra have testified before a Joint Congressional Committee about at-home drug deactivation.
- The manufacturers of Deterra have testified before the FDA to amend recommendation to expand to the use of at-home drug deactivation and disposal technology.
- Deterra is endorsed by the DEA Educational Foundation, The White House Office of National Drug Control Policy cited at-home deactivation technology in their Drug Control Policy 2.0
- The President's Commission on Combating Drug Addiction and the Opioid Crisis supported the use of drug deactivation pouches for disposal of unused prescription opioids.

Put Into Use

- Deterra was developed under a Small Business Innovation Research (SBIR) contract with the National Institute on Drug Abuse (NIDA).
- Attorneys General in Pennsylvania and Kentucky are currently distributing Deterra pouches throughout their states.
- Pending legislation has been put forth in multiple states to provide for at-home drug deactivation and disposal technology.
- Deterra enjoys many marquee clients in six market verticals.

The Deterra[®] drug deactivation system neutralizes drugs effectively, safely and quickly.

Each patented Deterra pouch contains a water-soluble inner pod containing MAT₁₂[®] activated carbon. Once the pharmaceuticals are placed in the pouch, warm water is then added, which dissolves the inner pod releasing the activated carbon. The warm water will also help dissolve pills and draw the drugs out of patches.



1
Tear open pouch and place unused medications inside



2
Fill pouch halfway with warm water and wait 30 seconds



3
Seal pouch tightly, gently shake and dispose of in normal trash

www.DeterraSystem.com



***Located
in Med
Room
under
epidural
pumps!***



This resource is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$499,057 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit [HRSA.gov](https://www.hrsa.gov).

